Cargando…
Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a rare hematological malignancy classified in the non-Hodgkin's lymphoma category. Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor has been approved for use in the treatment of CLL. This drug has shown beneficial effects including a...
Autores principales: | Zhou, Yanhua, Lu, Hongtao, Yang, Meifeng, Xu, Chenhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831170/ https://www.ncbi.nlm.nih.gov/pubmed/31415440 http://dx.doi.org/10.1097/MD.0000000000016915 |
Ejemplares similares
-
The impact of immune checkpoint inhibitors in patients with chronic lymphocytic leukemia (CLL): A protocol for a systematic review and meta-analysis of randomized controlled trials
por: Ntsethe, Aviwe, et al.
Publicado: (2020) -
Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report
por: Jiang, Qu, et al.
Publicado: (2017) -
Immune-related adverse events associated with the use of immunotherapy in patients with B-cell lymphoblastic leukemia: A protocol for a systematic review and meta-analysis
por: Kanovengi, Bianca K., et al.
Publicado: (2023) -
Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents: A protocol for systematic review and meta-analysis
por: Kassem, Nancy, et al.
Publicado: (2020) -
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)